Health.

“Obesity in men causes androgen deficiency.”

Obesity does appear to causally lower testosterone in men, and severe obesity can lead to genuine obesity-related hypogonadism. But the claim is too broad as stated: many obese men have lower total testosterone without true clinical androgen deficiency, because free testosterone may remain normal and the state is often functional and reversible. The evidence supports a real link, not the blanket formulation.

“In men, having too little body fat causes androgen levels to decrease.”

The evidence does not support the general claim that low body fat in men lowers androgens. High-quality studies more consistently show the opposite pattern: higher body fat is associated with lower testosterone, and reducing excess fat often improves it. A possible exception may exist in extreme leanness with severe energy deficit, but that is narrower and less well supported than the claim states.

“Being underweight in women causes excess androgen levels (hyperandrogenism).”

The evidence does not support underweight status as a cause of hyperandrogenism in women. Authoritative endocrine sources instead link underweight states such as functional hypothalamic amenorrhea and anorexia nervosa to low or normal androgen levels, while excess androgens are more commonly driven by PCOS, adrenal disorders, obesity, and insulin resistance. Rare lean-PCOS or atypical cases do not make underweight itself the cause.

“In men, having an excessive amount of body fat causes estrogen levels to become abnormally high.”

Excess body fat in men commonly raises estrogen production through increased aromatase activity, and many studies find higher estradiol or related estrogens in obese men. However, the effect is not universal, and serum estradiol is not always clearly or clinically abnormal in every study or every man. The claim is directionally accurate but stronger than the evidence warrants.

“Obesity in women causes estrogen deficiency.”

The evidence does not support the broad claim as stated. In some premenopausal contexts, obesity is associated with lower estradiol or altered hormone signaling, but after menopause obesity commonly raises estrogen levels because adipose tissue produces estrogen. That means the relationship is bidirectional and depends heavily on menopausal status, so describing obesity in women generally as causing estrogen deficiency is materially misleading.

“Women with insufficient body fat have reduced estrogen levels.”

The evidence strongly supports a real physiological link. Very low body fat is associated with lower estrogen because adipose tissue helps produce estrogen and because low fat often accompanies low energy availability, which can suppress ovarian hormone production. The main caveat is that there is no single body-fat percentage that defines "insufficient" for every woman.

“Being underweight in males causes excess estrogen levels.”

The evidence does not support underweight status as a cause of excess estrogen in males. Medical literature consistently links higher body fat—not low body weight—to higher estradiol because adipose tissue increases aromatization. In men, being underweight is more often associated with lower estrogen levels or broader hormonal suppression, not estrogen excess.

“Wasp stings can have a beneficial effect on osteoarthritis in a specific joint.”

Available evidence does not support the claim as stated. Research on wasp venom is limited to preclinical studies in inflammatory or rheumatoid arthritis models, not human osteoarthritis in a specific joint. The osteoarthritis evidence in the cited literature concerns bee venom—especially knee osteoarthritis—not wasp stings, so the claim overextends limited and mismatched findings.

“Profuse sweating with no apparent cause followed by a spasm-like sensation at the lower end of the esophagus is a warning sign of an impending myocardial infarction (heart attack).”

The evidence does not support this symptom pair as a recognized warning sign of an impending heart attack. Unexplained sweating can occur with myocardial infarction and should not be ignored, but a spasm-like sensation low in the esophagus is more commonly treated as an esophageal mimic or alternative diagnosis, not a cardiac prodrome. The claimed sequence is therefore materially misleading.

“Ex vivo CRISPR-based therapies for sickle cell disease typically require myeloablative conditioning with busulfan before reinfusion of edited hematopoietic stem cells.”

Current evidence shows busulfan-based myeloablation is the standard preparative step before reinfusion in ex vivo CRISPR sickle cell therapies. FDA labeling for Casgevy and published trial reports describe busulfan conditioning, and broader reviews say busulfan remains the usual regimen across these autologous ex vivo approaches. Alternative conditioning strategies exist in research, but they are not yet typical practice.

“Hydroxyurea treatment for sickle cell disease increases fetal hemoglobin production and reduces red blood cell sickling.”

The claim matches the established medical evidence. Hydroxyurea is a standard disease-modifying therapy for sickle cell disease because it raises fetal hemoglobin, which in turn suppresses hemoglobin S polymerization and reduces red blood cell sickling. Individual response varies, but that does not materially change the core conclusion.

“The 2021 Frangoul et al. report on CTX001 stated that the sickle cell disease patient had increased fetal hemoglobin and experienced no severe pain crises during approximately 16.6 months of follow-up.”

The claim matches the 2021 Frangoul et al. report. The paper states that the sickle cell disease patient had increased fetal hemoglobin after CTX001 and experienced no vaso-occlusive episodes during about 16.6 months of follow-up. A minor nuance is that some detailed HbF characterization was reported at a shorter timepoint, but that does not undermine the claim as written.

“Sickle cell disease is caused by inherited mutations in the HBB gene that produce hemoglobin S, which polymerizes under low-oxygen conditions and causes red blood cells to sickle and obstruct small blood vessels, leading to vaso-occlusive pain crises and organ damage.”

The claim accurately summarizes the core, well-established pathophysiology of sickle cell disease. Authoritative sources agree that inherited HBB mutations produce hemoglobin S, which polymerizes when deoxygenated, causing red cells to sickle, impair flow in small vessels, trigger vaso-occlusive pain crises, and contribute to organ damage. Additional inflammatory and adhesion mechanisms exist, but they do not overturn this central mechanism.

“Long-term regular blood transfusions for sickle cell disease can cause iron overload.”

Long-term regular transfusions in sickle cell disease are a well-established cause of transfusional iron overload. Multiple authoritative reviews and clinical studies show that repeated transfusions add iron faster than the body can remove it, causing iron accumulation over time. The risk may be lower with some exchange-based regimens, but the claim itself is accurate.

“In women, lower levels of estrogen are associated with faster toenail growth.”

The available evidence points in the opposite direction. Sources discussing menopause and nail biology associate lower estrogen with slower nail growth and increased brittleness, while higher-estrogen states are described as linked to faster growth. The main quantitative toenail-growth study provides no estrogen association, so the claim is not supported as stated.

“Skullcap (Scutellaria) herb is effective for preventing some cancers.”

The evidence does not show that skullcap herb is effective for preventing cancer in humans. Research on Scutellaria and its flavonoids is largely preclinical, involving cell lines, animal models, and mechanistic studies, while authoritative medical sources note the lack of good human evidence for cancer prevention. The claim overstates early laboratory findings as proven real-world preventive efficacy.

“In adult dreams, 99% of dream experiences are from a first-person viewpoint rather than a third-person viewpoint.”

The evidence does not support a 99% first-person rate in adult dreams. The strongest peer-reviewed studies cited report first-person perspective as common, but closer to roughly the low-80s, while third-person or observer dreams remain a meaningful minority. The claim also overstates what the studies measure by blurring dominant dream perspective, individual dream episodes, and unrelated dream-recall statistics.

“The SARS-CoV-2 Omicron XBB subvariant is lethal and is not easy to detect.”

The claim overstates both the danger and the diagnostic difficulty of XBB. Authoritative human data show XBB was not unusually deadly compared with other Omicron lineages, even though severe illness and death could still occur in high-risk people. Standard COVID-19 tests continued to detect XBB; only some specific assay targets or variant-tracking markers were affected.

“Sitting on a cold floor causes ovarian health problems.”

The evidence does not support the claim. Authoritative human health sources do not recognize sitting on a cold floor as a cause of ovarian problems, and available studies showing ovarian effects involve prolonged whole-body cold exposure in rodents, not ordinary human contact with a cold surface. The claim relies on a folklore-style extrapolation rather than demonstrated human evidence.

“The Bogalusa Heart Study was a long-term study that followed children's cardiovascular health into adulthood and found evidence that cardiovascular disease can begin in childhood.”

The evidence strongly supports this description of the Bogalusa Heart Study. It was a long-running longitudinal study that followed children into adulthood, and its autopsy and follow-up findings helped show that atherosclerotic cardiovascular disease processes can start in childhood. The wording is appropriately cautious because it refers to evidence of early disease development, not typical childhood heart attacks.